Recombinant human papillomavirus nonavalent vaccine

A vaccine that is FDA-approved for use in females and males aged 9 to 45 years to prevent infection with the nine types of human papillomavirus (HPV) that most often cause genital warts, certain precancerous lesions, and cancers of the cervix, vagina, vulva, anus, and head and neck, including the oropharynx. Recombinant human papillomavirus nonavalent vaccine may also prevent HPV-related cancer of the penis. Also called Gardasil 9.